Details of issuance or disposal
Exercise status and completion report for the 16th Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment provisions)
Shares delivered since the beginning of the month: 210,000 shares (210,000 new shares and 0 treasury shares transferred)
The lower thin line represents the existing number of shares to which these shares will be added.
3.1% (exercise ratio subject to exercise restrictions; 210,000 shares delivered across all series / 6,837,200 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status and completion report for the 16th Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment provisions) |
| Number of shares to be issued or disposed of | Shares delivered since the beginning of the month: 210,000 shares (210,000 new shares and 0 treasury shares transferred) |
| Intended allottee | EVO FUND (the allottee at the time of issuance on 1 August 2025) |
| Dilution Rate | 3.1% (exercise ratio subject to exercise restrictions; 210,000 shares delivered across all series / 6,837,200 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 8,383,200 shares (as of 30 July 2026, including 183 treasury shares) → Not disclosed |
| Exercise price | ¥416, ¥425 and ¥436 (as stated in the August 2026 exercise status). Details of the adjustment provisions and the floor price: not disclosed |
| Number of Stock Acquisition Rights | Total issued: 17,000 rights; unexercised at the end of the previous month: 2,100 rights; currently unexercised: 0 rights |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Timing 1 August 2025 / Type 16th Stock Acquisition Rights (with an exercise price adjustment clause), with EVO FUND as the allottee / Amount Not disclosed |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company does not state a reason.